Bonnie Anderson - Veracyte CEO
| VCYT Stock | USD 44.12 1.17 2.72% |
CEO
Ms. Bonnie H. Anderson serves as Chairman of the Board, Chief Executive Officer of the Company. She has served as our cofounder, Chief Executive Officer and as a member of our board of directors since February 2008 and as the Chairman of our board of directors since December 2016. From August 2013 to February 2017, she also served as our President. Prior to joining us, Ms. Anderson was an independent strategic consultant from April 2006 to January 2008, including as a strategic consultant for us from July 2007 to January 2008. Ms. Anderson was a Vice President at Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, from September 2000 to March 2006. Ms. Anderson currently serves as a member of the board of directors of Castle Biosciences, Inc. and as a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences since 2017.
| Age | 66 |
| Tenure | 7 years |
| Address | 6000 Shoreline Court, South San Francisco, CA, United States, 94080 |
| Phone | 650 243 6300 |
| Web | https://www.veracyte.com |
Veracyte Management Efficiency
The company has return on total asset (ROA) of 0.0107 % which means that it generated a profit of $0.0107 on every $100 spent on assets. This is way below average. Veracyte's management efficiency ratios could be used to measure how well Veracyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.09 in 2024. At this time, Veracyte's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 1.2 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 1.2 M in 2024.Similar Executives
| Found 7 records | CEO Age | ||
| Jay Luly | Enanta Pharmaceuticals | 68 | |
| MBA JD | Viridian Therapeutics | 54 | |
| Robert Blum | Cytokinetics | 60 | |
| Scott Struthers | Crinetics Pharmaceuticals | 61 | |
| Raymond Stevens | Structure Therapeutics American | 60 | |
| Robert Coffin | Replimune Group | 59 | |
| Dinesh Patel | Protagonist Therapeutics | 67 | |
Management Performance
| Return On Equity | -0.0083 | ||||
| Return On Asset | 0.0107 |
Veracyte Leadership Team
Elected by the shareholders, the Veracyte's board of directors comprises two types of representatives: Veracyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veracyte. The board's role is to monitor Veracyte's management team and ensure that shareholders' interests are well served. Veracyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veracyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Brainin, Executive Officer | ||
| John Leite, Chief Business | ||
| Annie McGuire, Sr Counsel | ||
| Tracy Morris, VP Communications | ||
| Corinne Danan, Senior President | ||
| Tina Nova, Director | ||
| Bonnie Anderson, Co-Founder, CEO and President Director and Member of Non-Management Equity Award Committee | ||
| Keith Gligorich, Senior Operations | ||
| Rebecca Chambers, Executive CFO | ||
| Jonathan Wygant, VP Officer | ||
| Phillip MD, Chief Officer | ||
| Beverly CPA, VP Controller | ||
| Karen Possemato, Communications Marketing | ||
| Giulia Kennedy, Chief Scientific Officer, Chief Medical Officer | ||
| Steven French, Senior Officer | ||
| Marc Stapley, CEO Director |
Veracyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veracyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0083 | ||||
| Return On Asset | 0.0107 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 3.07 B | ||||
| Shares Outstanding | 77.5 M | ||||
| Shares Owned By Insiders | 0.77 % | ||||
| Shares Owned By Institutions | 99.23 % | ||||
| Number Of Shares Shorted | 2.88 M | ||||
| Price To Earning | (10.61) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.